Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer.

Williams JA Jr, Wang ZR, Parrish RS, Hazlett LJ, Smith ST, Young SR.

Exp Mol Pathol. 1999 Dec;67(3):135-43.

PMID:
10600396
3.

Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.

Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.

Cancer Res. 1995 Dec 1;55(23):5693-8.

4.

HER-2/neu amplification and overexpression in endometrial carcinoma.

Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH.

Int J Gynecol Pathol. 1999 Apr;18(2):138-43.

PMID:
10202671
5.

c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.

Wang ZR, Liu W, Smith ST, Parrish RS, Young SR.

Exp Mol Pathol. 1999 Jun;66(2):140-8.

PMID:
10409442
6.

Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.

Riben MW, Malfetano JH, Nazeer T, Muraca PJ, Ambros RA, Ross JS.

Mod Pathol. 1997 Aug;10(8):823-31.

PMID:
9267826
7.

Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.

Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB.

Mod Pathol. 2002 Jan;15(1):35-44.

8.

HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.

Tan D, Deeb G, Wang J, Slocum HK, Winston J, Wiseman S, Beck A, Sait S, Anderson T, Nwogu C, Ramnath N, Loewen G.

Diagn Mol Pathol. 2003 Dec;12(4):201-11.

PMID:
14639106
9.

Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.

Ismail MF, Aly MS, Khaled HM, Mohamed HM.

Ger Med Sci. 2009 May 6;7:Doc03. doi: 10.3205/000062.

10.

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.

Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S.

Cancer. 2005 Oct 1;104(7):1391-7.

11.
12.

HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis.

Tsai JY, Aviv H, Benevenia J, Chang VT, Patterson F, Aisner S, Hameed M.

Cancer Invest. 2004;22(1):16-24.

PMID:
15069760
13.

P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression.

Coronado PJ, Vidart JA, Lopez-asenjo JA, Fasero M, Furio-bacete V, Magrina J, Escudero M.

Eur J Obstet Gynecol Reprod Biol. 2001 Sep;98(1):103-8.

PMID:
11516808
14.

HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters.

Cianciulli AM, Guadagni F, Marzano R, Benevolo M, Merola R, Giannarelli D, Marandino F, Vocaturo G, Mariani L, Mottolese M.

J Exp Clin Cancer Res. 2003 Jun;22(2):265-71.

PMID:
12866577
15.

Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.

Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G, Insabato L.

Int J Surg Pathol. 2009 Jun;17(3):198-205. doi: 10.1177/1066896909333415.

PMID:
19443884
16.

HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.

Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM.

J Clin Oncol. 2006 May 20;24(15):2376-85. Erratum in: J Clin Oncol. 2006 Jul 20;24(21):3515. Maxwell, Larry G [corrected to Maxwell, G Larry].

PMID:
16710036
17.

Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.

Jongen VH, Briët JM, de Jong RA, Joppe E, ten Hoor KA, Boezen HM, Evans DB, Hollema H, van der Zee AG, Nijman HW.

Int J Gynecol Cancer. 2009 May;19(4):670-6. doi: 10.1111/IGC.0b013e3181a47c25.

PMID:
19509570
18.

HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.

Odicino FE, Bignotti E, Rossi E, Pasinetti B, Tassi RA, Donzelli C, Falchetti M, Fontana P, Grigolato PG, Pecorelli S.

Int J Gynecol Cancer. 2008 Jan-Feb;18(1):14-21. Epub 2007 Apr 19.

PMID:
17451461
19.

Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers.

Janocko LE, Brown KA, Smith CA, Gu LP, Pollice AA, Singh SG, Julian T, Wolmark N, Sweeney L, Silverman JF, Shackney SE.

Cytometry. 2001 Jun 15;46(3):136-49.

PMID:
11449404
20.

Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer.

Monk BJ, Chapman JA, Johnson GA, Brightman BK, Wilczynski SP, Schell MJ, Fan H.

Am J Obstet Gynecol. 1994 Nov;171(5):1193-8.

PMID:
7977518

Supplemental Content

Support Center